Haleon stock trades steady as oral health and pain relief drive growth
Published on 07/20/2026 at 19:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Haleon stock represents the London listed consumer health specialist Haleon plc (ISIN GB00BMX86B70), which reported group revenue of about GBP 11 billion for fiscal 2023, up roughly in the low single digit percentage range compared with fiscal 2022, according to the company’s annual reporting as of 31 December 2023. The revenue increase was driven mostly by price and mix as Haleon continued to emphasize branded oral health and pain relief products, based on the group’s description of its performance in the 2023 reporting cycle.
Revenue up low single digits
According to Haleon’s 2023 annual and sustainability reporting, net revenue for the year to 31 December 2023 was around GBP 11 billion, an increase in the low single digit percentage range versus the prior year’s roughly GBP 10.6 billion level. Within this total, the oral health business recorded mid single digit percentage revenue growth year on year in 2023, supported by continued demand for everyday products such as toothpaste and mouthwash, while the pain relief portfolio delivered similar mid single digit growth compared with 2022. The company explained that pricing and product mix contributed more to this improvement than volume in some mature markets, but volumes remained positive in a number of emerging regions.
Haleon’s adjusted operating profit for 2023 also increased, with the company indicating an improvement in the mid single digit percentage range versus 2022, reflecting both higher revenue and disciplined cost management across manufacturing and marketing functions. The adjusted operating margin therefore expanded slightly in 2023 relative to the previous year, helped by efficiencies in supply chain operations and a focus on higher margin branded products in categories such as oral health and pain relief. For investors, this combination of revenue growth and margin expansion underlines the company’s ability to pass on cost inflation in the consumer health market while maintaining volumes.
Spin off capital structure and cash flow
Haleon was formed as a standalone listed company following its spin off from GSK, and the group’s 2023 financials show a focused capital structure built around the consumer health portfolio. As of 31 December 2023, Haleon reported net debt in the low tens of billions of GBP, balanced against its earnings and cash flow so that leverage remained within the company’s stated target range. The group generated solid free cash flow in 2023, with cash generated from operations comfortably covering interest, tax, and capital expenditure, and allowing for continued investment in brands and innovation pipeline.
Haleon’s 2023 reporting also highlighted that the company’s portfolio is arranged around three main segments: oral health, pain relief, and a broader wellness category including respiratory and digestive brands. Revenue in oral health reached several billion GBP in 2023, reflecting mid single digit growth versus 2022; pain relief contributed a similar multi billion GBP figure, with mid single digit year on year improvement; and the rest of the wellness portfolio added the remaining portion of the approximate GBP 11 billion group revenue. This segmentation is important for investors who track how each category contributes to overall growth and margin profile.
More on Haleon earnings and segments
The investor relations section offers detailed tables on Haleon’s 2023 revenue, profit, cash flow, and segment performance across oral health, pain relief, and other wellness categories.
Oral health brands and 2023 performance
Haleon’s oral health portfolio includes well known brands in toothbrushes, toothpaste, mouthwash, and specialized products for sensitive teeth and gum health. In its 2023 reporting, the company highlighted that oral health revenue grew in the mid single digit percentage range year on year, supported by innovation and geographic expansion. New product variants and targeted advertising campaigns contributed to higher average selling prices, while the company’s distribution network ensured steady availability in retail and pharmacy channels across Europe, North America, and selected emerging markets.
For investors analyzing Haleon stock, the oral health segment’s performance matters because it is associated with relatively high margins compared with some other consumer health categories. The company’s 2023 data suggests that oral health contributed a significant share of the group’s adjusted operating profit, reflecting both branded pricing power and ongoing cost discipline in production and packaging. This positions Haleon to continue investing in research and development for oral care while maintaining financial flexibility.
Pain relief and everyday health products
Haleon’s pain relief portfolio covers over the counter medicines for headaches, muscle pain, joint pain, and everyday aches, with brands that are positioned in pharmacies and mass retail outlets. According to the 2023 annual reporting, pain relief revenue grew in the mid single digit percentage range compared with 2022, similar to the oral health segment, supported by both price increases and stable to slightly higher volumes. Seasonal factors such as flu and cold periods, as well as ongoing consumer demand for self care solutions, contributed to this performance.
The pain relief segment also plays a role in Haleon’s margin profile, though margins can vary depending on active ingredients, regulatory environments, and marketing requirements in each country. In 2023, Haleon continued to balance investment in brand awareness with efficiency measures in procurement and manufacturing, helping to support adjusted operating profit expansion in the mid single digit percentage range versus 2022. For investors, the stability of pain relief demand provides a foundation for predictable cash flows, even as Haleon adjusts its portfolio in response to regulation and competition.
Everyday wellness and regional trends
Beyond oral health and pain relief, Haleon’s everyday wellness portfolio includes respiratory products, vitamins and supplements, and digestive health brands. In 2023, the company recorded mixed trends in these categories, with some markets showing stronger growth than others, but overall contributing positively to the approximate GBP 11 billion in group revenue. Emerging markets in Asia and Latin America offered growth opportunities, while mature markets in Europe and North America saw a combination of price led and volume driven performance.
Haleon’s geographic mix is relevant for investors tracking currency exposure and growth potential. A substantial portion of revenue is generated in Western currencies such as GBP, EUR, and USD, but the company also earns in a range of other currencies through its operations in emerging regions. In its 2023 reporting, Haleon noted that it manages foreign exchange exposure through a combination of operational hedging and financial instruments, seeking to limit volatility in reported earnings.
Representative product line in oral health
One representative product line within Haleon’s portfolio is its range of toothpaste and oral care products designed for sensitive teeth and gum health, which sit under globally recognized brand names. These toothpaste products contribute significantly to oral health revenue, which grew in the mid single digit percentage range in 2023 compared with 2022. The product line addresses everyday needs such as sensitivity to hot and cold foods, and supports long term oral hygiene, aligning with Haleon’s focus on preventive consumer health.
Haleon stock and market context
Haleon stock is listed on the London Stock Exchange, where it trades in GBX, the pence unit for UK equities. In the months following the publication of the 2023 annual results, the share price has reflected the market’s view of Haleon’s steady revenue growth, mid single digit margin expansion, and moderate leverage level. The company’s approximate market capitalization stands in the multi billion GBP range, placing it among the larger consumer health focused issuers in the UK market. For investors, Haleon’s combination of predictable cash flows, branded product portfolio, and focus on oral health and pain relief offers a distinct profile compared with diversified pharmaceutical or consumer goods groups.
Haleon at a glance
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Ticker: LSE: HLN
- Trading venue: London Stock Exchange
- Market capitalization: multi billion GBP range (as of 31 December 2023)
- Sector / Industry: Consumer Health / Pharmaceuticals and Personal Care
- Index membership: FTSE 100
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
